(Q46254891)

English

Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

0 references

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Sheila M J Aubin

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

Jennifer Reid

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

Mark J Sarno

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

Amy Blase

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

Jacqueline Aussie

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

Harry Rittenhouse

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

Roger S Rittmaster

7

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

Gerald L Andriole

8

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

Jack Groskopf

9

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

language of work or name

0 references

publication date

1 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

78

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

380-385

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

PCA3: a molecular urine assay for predicting prostate biopsy outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

PCA3 Molecular Urine Test for Predicting Repeat Prostate Biopsy Outcome in Populations at Risk: Validation in the Placebo Arm of the Dutasteride REDUCE Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

Effect of dutasteride on the risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

New targets for therapy in prostate cancer: differential display code 3 (DD3PCA3), a highly prostate cancer–specific gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

Androgen receptor and prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

Does the level of prostate cancer risk affect cancer prevention with finasteride?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.033

7 January 2021

Identifiers

10.1016/J.UROLOGY.2011.03.033

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21820580

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46254891&oldid=2102265970"